CBD-rich cannabis oil improved Crohn's symptoms and quality of life but not gut inflammation
In a double-blind RCT of 56 Crohn's disease patients, 8 weeks of CBD-rich cannabis oil significantly improved symptom scores and quality of life compared to placebo, but endoscopic scores and inflammatory markers were unchanged.
Quick Facts
What This Study Found
CDAI dropped from 282 to 166 in the cannabis group vs 264 to 237 in placebo (P < 0.05). Quality of life improved from 74 to 91 in cannabis vs 74 to 75 in placebo (P = 0.004). However, endoscopic scores (SES-CD) did not differ between groups (P = 0.75), and CRP and calprotectin remained unchanged.
Key Numbers
56 patients (30 cannabis, 26 placebo); CBD:THC 160:40 mg/ml; CDAI: 282→166 cannabis vs 264→237 placebo; QOL: 74→91 vs 74→75; SES-CD: P = 0.75; CRP and calprotectin unchanged
How They Did This
Double-blind, randomized, placebo-controlled, single-center trial. 56 patients received either CBD-rich cannabis oil (160/40 mg/ml CBD/THC) or placebo orally for 8 weeks. Disease activity (CDAI), endoscopic score (SES-CD), quality of life, and inflammatory markers were assessed.
Why This Research Matters
This is one of the few controlled trials of cannabis in Crohn's disease with endoscopic endpoints. The dissociation between symptom improvement and unchanged inflammation raises a critical question: is cannabis treating the disease or just masking symptoms?
The Bigger Picture
The finding that patients feel better without objective improvement in gut inflammation is a double-edged sword. Symptom relief improves quality of life, but if patients reduce evidence-based therapies because they feel better, untreated inflammation could lead to complications.
What This Study Doesn't Tell Us
Single center. Small sample. 8-week duration may be insufficient for endoscopic improvement. Fixed CBD:THC ratio may not be optimal. No long-term follow-up.
Questions This Raises
- ?Would longer treatment produce endoscopic improvement?
- ?Is a different CBD:THC ratio more effective?
- ?Should cannabis be used as adjunctive therapy alongside conventional IBD treatments?
- ?Is there a risk of patients discontinuing effective therapies because cannabis makes them feel better?
Trust & Context
- Key Stat:
- Symptoms improved (P < 0.05) but gut inflammation unchanged (P = 0.75)
- Evidence Grade:
- Well-designed double-blind RCT with endoscopic endpoints, though single center and relatively small sample.
- Study Age:
- Published in 2021.
- Original Title:
- Oral CBD-rich Cannabis Induces Clinical but Not Endoscopic Response in Patients with Crohn's Disease, a Randomised Controlled Trial.
- Published In:
- Journal of Crohn's & colitis, 15(11), 1799-1806 (2021)
- Authors:
- Naftali, Timna(8), Bar-Lev Schleider, Lihi(7), Almog, Shlomo, Meiri, David, Konikoff, Fred M
- Database ID:
- RTHC-03372
Evidence Hierarchy
Participants are randomly assigned to treatment or placebo groups to test cause and effect.
What do these levels mean? →Frequently Asked Questions
Does cannabis help Crohn's disease?
CBD-rich cannabis oil improved symptoms and quality of life in this trial, but did not reduce gut inflammation as measured by endoscopy and blood markers. This suggests cannabis may help patients feel better without treating the underlying disease.
Should Crohn's patients replace their medications with cannabis?
The researchers cautioned that cannabis treatment should only be used in the context of clinical trials until more data is available, particularly since inflammation was not reduced despite symptom improvement.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-03372APA
Naftali, Timna; Bar-Lev Schleider, Lihi; Almog, Shlomo; Meiri, David; Konikoff, Fred M. (2021). Oral CBD-rich Cannabis Induces Clinical but Not Endoscopic Response in Patients with Crohn's Disease, a Randomised Controlled Trial.. Journal of Crohn's & colitis, 15(11), 1799-1806. https://doi.org/10.1093/ecco-jcc/jjab069
MLA
Naftali, Timna, et al. "Oral CBD-rich Cannabis Induces Clinical but Not Endoscopic Response in Patients with Crohn's Disease, a Randomised Controlled Trial.." Journal of Crohn's & colitis, 2021. https://doi.org/10.1093/ecco-jcc/jjab069
RethinkTHC
RethinkTHC Research Database. "Oral CBD-rich Cannabis Induces Clinical but Not Endoscopic R..." RTHC-03372. Retrieved from https://rethinkthc.com/research/naftali-2021-oral-cbdrich-cannabis-induces
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.